Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 472 clinical trials
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospectivemulti-centeropen-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

t-cell lymphoma
peripheral t-cell lymphoma
measurable disease
pet/ct scan
lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

paclitaxel
camrelizumab
antibody therapy
chemoradiotherapy
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

cutaneous t cell lymphoma
non-hodgkin lymphoma
metastatic cancer
renal function test
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS CMML or AML

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose …

graft versus host disease
major surgery
chronic myeloid leukemia
acute leukemia
immunosuppressive agents
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …

measurable disease
solid tumor
solid tumour
colorectal cancer
serum pregnancy test
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

antineoplastic agents
paclitaxel
pancreatic adenocarcinoma
measurable disease
breast ductal carcinoma
  • 0 views
  • 19 Feb, 2024
  • 8 locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

erbb1
palbociclib
epidermal growth factor receptor
estrogen
stage iv breast cancer
  • 0 views
  • 19 Feb, 2024
  • 7 locations
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial

myocardial infarction
lipase
carcinoma in situ
unstable angina
pancreatitis
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

erbb1
egf receptors
measurable disease
solid tumor
epidermal growth factor receptor
  • 0 views
  • 19 Feb, 2024
  • 39 locations
Combination Immunotherapy Targeting Sarcomas

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines …

sarcoma
immunosuppression
steroid hormone
immunosuppressive
renal function
  • 0 views
  • 19 Feb, 2024
  • 2 locations